FivepHusion is an advanced clinical-stage biotech company dedicated to improving treatment outcomes and quality of life for cancer patients.

We are addressing the safety and efficacy limitations of standard of care (SOC) cancer therapy via the development of Deflexifol™, a next-generation, novel drug co-formulation enabling the optimised delivery of SOC 5-fluorouracil (5-FU) chemotherapy with its biomodulator leucovorin, a drug that enhances 5-FU anticancer activity. Deflexifol™ offers superior safety, tolerability, and anti-tumour activity for various solid tumour indications currently treated with 5-FU, including colorectal, breast, pancreatic, and other gastrointestinal cancers; and is also in development as a promising new therapy for various paediatric brain cancers.

Deflexifol™ development is currently focused on preparatory activities required prior to initiation of global pivotal studies in the 1st line treatment of metastatic colorectal cancer (mCRC), and as potentially the first approved therapy for the orphan brain cancer indication, paediatric ependymoma. Our partners include Syneos Health, Pfizer CentreOne and Allarity Therapeutics.

The Deflexifol™ commercial opportunities are very attractive as an optimised therapy for mCRC, a significant US$12.6B market (2021, + 2.6% CAGR), and as one of few treatment options for paediatric brain cancers (US$1.65B market in 2023 + 4.1% CAGR). An upside opportunity is replacement of 5-FU as SOC therapy for cancers with >6M patient global incidence.

We are seeking investment and further strategic global and regional partnerships to support accelerated development and commercialisation of Deflexifol™.